Q3 EPS Estimates for Krystal Biotech Cut by William Blair

Key Points

• William Blair has reduced their Q3 2025 earnings per share estimate for Krystal Biotech from $1.14 to $1.11.
• The consensus estimate for Krystal Biotech's total earnings for the current full year is $6.14 per share.
• Insider transactions revealed that Suma Krishnan sold over 3,000 shares of Krystal Biotech, which represents a 0.20% decrease in their position.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for shares of Krystal Biotech in a note issued to investors on Friday, October 10th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of $1.11 for the quarter, down from their previous forecast of $1.14. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's FY2025 earnings at $5.16 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million.

Several other research analysts have also weighed in on the company. Chardan Capital lowered their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Bank of America decreased their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Citigroup reaffirmed a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $209.00.

Krystal Biotech Trading Down 3.9%

KRYS stock opened at $181.47 on Monday. The stock has a 50-day moving average price of $155.47 and a 200-day moving average price of $150.77. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $207.84. The firm has a market cap of $5.25 billion, a PE ratio of 36.88 and a beta of 0.64.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 3,084 shares of Krystal Biotech stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $151.01, for a total transaction of $465,714.84. Following the completion of the transaction, the insider owned 1,509,445 shares in the company, valued at approximately $227,941,289.45. The trade was a 0.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 9,038 shares of company stock worth $1,361,790. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently added to or reduced their stakes in KRYS. Soleus Capital Management L.P. boosted its stake in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock valued at $126,870,000 after purchasing an additional 481,200 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after buying an additional 365,304 shares during the last quarter. Braidwell LP boosted its stake in shares of Krystal Biotech by 81.6% in the 2nd quarter. Braidwell LP now owns 727,811 shares of the company's stock worth $100,045,000 after buying an additional 327,067 shares during the last quarter. Norges Bank purchased a new position in shares of Krystal Biotech in the 2nd quarter worth approximately $38,861,000. Finally, Nuveen LLC purchased a new position in shares of Krystal Biotech in the 1st quarter worth approximately $42,223,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.